COVID-19 (coronavirus disease 2019) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a virus of the coronavirus family. A cluster of pneumonia cases of unknown cause was reported in Wuhan, China, in December 2019, and the World Health Organization later declared the outbreak a COVID-19 pandemic. The disease spreads mainly through respiratory droplets and aerosols. Its course ranges from asymptomatic infection to severe pneumonia and death, and it can leave some patients with persistent symptoms known as long COVID. Its scale made it one of the most consequential public health events of the early twenty-first century, and it drove rapid advances in vaccine development, viral evolution research, and epidemiological modelling.
The entry explains the biology of the pathogen and the disease, then follows the clinical picture, diagnosis, prevention and treatment, and the public health measures and policy choices that shaped the pandemic. It also covers the epidemiological record, the economic and social consequences, and the questions that remain open, including the origin of the virus, the long-term burden of long COVID, and the future of pandemic preparedness through institutions such as the World Health Organization. Throughout, the entry relies on the scientific consensus and on figures from authoritative bodies, and it notes where evidence is still incomplete.
The causative virus: SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped virus with a positive-sense, single-stranded RNA genome. It belongs to the coronavirus family Coronaviridae, genus Betacoronavirus, and subgenus Sarbecovirus. SARS-CoV, the virus responsible for the 2002–2003 severe acute respiratory syndrome outbreak, belongs to the same subgenus and species; the species is now named Betacoronavirus pandemicum, formerly Severe acute respiratory syndrome-related coronavirus. MERS-CoV, which causes Middle East respiratory syndrome, is also a betacoronavirus but belongs to the distinct subgenus Merbecovirus. These classifications reflect evolutionary relationships, particularly similarities among conserved replication proteins, rather than an assumption that the viruses cause identical diseases. (nature.com)
The virion consists of a lipid envelope surrounding RNA associated with nucleocapsid (N) protein. Three other principal structural proteins occupy the envelope: membrane (M), envelope (E), and spike (S) protein. M contributes to particle organization, E participates in assembly, and S forms the projecting trimers that attach to host cells and mediate membrane fusion. The projections produce the crown-like appearance underlying the name “coronavirus.” Particle shape and dimensions vary: in a 2020 cryo-electron tomography study, Hangping Yao and colleagues examined 2,294 virions and measured mean envelope dimensions of approximately 65, 86, and 97 nanometres along their three axes. Their analysis found an average of 26 prefusion spike trimers per particle, illustrating that spike density is not a fixed geometric property. (ictv.global)
The early reference genome contains 29,903 nucleotides. Its positive sense means that the incoming RNA can serve directly as messenger RNA for host-cell ribosomes. Approximately the first two-thirds contain the overlapping open reading frames ORF1a and ORF1b. Translation produces the polyprotein pp1a or, through a programmed ribosomal frameshift, the longer pp1ab; viral proteases cleave these precursors into non-structural proteins, including the RNA-dependent RNA polymerase and other components of the replication machinery. The downstream region contains genes for S, E, M, and N, interspersed with accessory genes. These downstream genes are expressed through a nested set of subgenomic messenger RNAs, rather than by translating the entire genome as one continuous protein. (nature.com)
Spike comprises a receptor-binding S1 portion and a membrane-fusion S2 portion. Within S1, the receptor-binding domain recognizes angiotensin-converting enzyme 2 (ACE2), a host-cell surface protein also used by SARS-CoV. In 2020, Jun Lan and colleagues determined the crystal structure of the SARS-CoV-2 receptor-binding domain bound to human ACE2, identifying the molecular interface through which attachment occurs. Binding alone does not complete entry: host proteases activate spike, allowing S2 to drive fusion between viral and cellular membranes. Markus Hoffmann and colleagues demonstrated ACE2-dependent entry and spike activation by the cell-surface protease TMPRSS2; entry can also involve endosomal proteases. These mechanisms explain how the viral genome reaches the cell cytoplasm, without implying that receptor expression alone determines tissue susceptibility. (nature.com)
Initially designated 2019-nCoV, meaning “2019 novel coronavirus,” the virus received the name SARS-CoV-2 from the International Committee on Taxonomy of Viruses’ Coronaviridae Study Group, announced on 11 February 2020. The name reflected its taxonomic relationship to SARS-associated coronaviruses, not a designation of the illness as SARS. On the same date, the World Health Organization announced COVID-19, short for “coronavirus disease 2019,” as the disease name. SARS-CoV-2 therefore names the infectious agent, whereas COVID-19 names the disease it causes; the two terms are not interchangeable. (nature.com)
Origin and early emergence
The recognized outbreak began with reports of unexplained pneumonia in Wuhan, Hubei province, China, in December 2019. On 31 December, the World Health Organization (WHO) China Country Office was informed of the cluster; by 3 January 2020, Chinese authorities had reported 44 patients, including 11 who were severely ill. These were initially reports of a clinical syndrome, not laboratory-confirmed COVID-19. Chinese authorities identified and isolated a novel coronavirus on 7 January. WHO reported that China shared its genetic sequence on 12 January, enabling the development of pathogen-specific diagnostic tests. The Huanan Seafood Wholesale Market, an early focus of investigation, had closed on 1 January. (who.int)
Early patient series established a substantial market-associated cluster but did not identify the first human infection. In a study published in January 2020, Chaolin Huang and colleagues described 41 hospitalized patients with laboratory-confirmed infection identified by 2 January: 27, or 66%, had exposure to the Huanan market. The paper reported symptom onset on 1 December 2019 for its earliest patient, who had no identified market connection. Such dates represent retrospective clinical histories rather than a verified “patient zero.” Initial surveillance emphasized hospitalized pneumonia, leaving mild or symptom-free infections poorly represented, while the completeness of early case records and the effects of case-selection criteria complicate reconstruction of the outbreak. SAGO’s subsequent assessment could not establish exactly when, where, or how the virus first entered humans. (idsociety.org)
Later epidemiological and environmental analyses strengthened the evidence connecting early emergence to the market. Michael Worobey and colleagues’ 2022 study mapped 155 December cases and found that their residences—including those without reported direct market exposure—were geographically concentrated around Huanan. The market sold live mammals susceptible to SARS-CoV-2, and virus-positive environmental samples were associated with areas where live mammals were sold. A 2024 study led by Alexander Crits-Christoph found genetic material from wildlife, including raccoon dogs, in environmental samples containing SARS-CoV-2. These findings are consistent with a market-associated animal-to-human emergence, but co-detection in a surface sample does not establish that an animal was infected: infected people could also deposit viral material. No animal carrying the immediate progenitor of SARS-CoV-2 has been identified. (pmc.ncbi.nlm.nih.gov)
Early genomic comparisons independently established the virus’s close evolutionary relationship to bat coronaviruses. In February 2020, Peng Zhou and colleagues reported that SARS-CoV-2 shared 96.2% whole-genome sequence identity with RaTG13, a coronavirus sequence obtained from a Rhinolophus affinis bat sample from Yunnan. This supported ancestry within bat-associated coronaviruses, but RaTG13 was not the immediate ancestral virus responsible for the outbreak. Genetic relatedness alone cannot reconstruct the route from an animal reservoir to humans or distinguish direct bat-to-human transmission from transmission through an intermediate mammalian host. (nature.com)
The principal origin hypotheses are zoonotic spillover—directly from bats or through an intermediate host—and a laboratory-related introduction, such as accidental infection during research or field collection. In its assessment released on 27 June 2025, WHO’s Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) concluded that the weight of available evidence favoured zoonotic spillover, while the precise origin remained unresolved. It could not adequately evaluate a laboratory-related origin because necessary information had not been supplied. Outstanding material included early patient sequences, detailed records of animals sold in Wuhan markets, and information about research activities and biosafety conditions in Wuhan laboratories. These evidentiary gaps prevent a definitive reconstruction; they do not establish that the competing hypotheses have equal empirical support. (cdn.who.int)
Transmission and incubation
SARS-CoV-2 spreads predominantly through respiratory particles released when an infected person breathes, speaks, sings, coughs or sneezes. Infection can occur through inhalation of virus-containing aerosols and small droplets, or through direct deposition of respiratory particles on the exposed mucous membranes of the eyes, nose or mouth. Close contact increases exposure because concentrations of exhaled particles are generally highest near their source; it does not necessarily imply physical touching. Larger droplets tend to settle more rapidly, whereas finer particles remain suspended and move with air currents. Contaminated objects and surfaces, termed fomites, provide another possible route when virus is transferred to the hands and subsequently to mucous membranes, but this route contributes much less to transmission than respiratory exposure. (archive.cdc.gov)
Airborne transmission can occur beyond the immediate vicinity of an infected person. Poorly ventilated enclosed spaces allow infectious particles to accumulate, particularly during prolonged occupancy. Singing, shouting and exercise increase respiratory emissions, while longer exposure increases the opportunity to inhale infectious particles. Aerosols may remain in an indoor space after their source has departed. Distance therefore reduces exposure to concentrated exhalations but does not, by itself, eliminate exposure to shared indoor air. These mechanisms explain why crowded indoor gatherings can produce infections among people who have had no direct physical contact. (archive.cdc.gov)
The incubation period is the interval between infection and the onset of symptoms, rather than the interval before a person becomes infectious. Its distribution has differed across viral variants. The US Centers for Disease Control and Prevention reports that meta-analyses of studies published in 2020 found a pooled mean of approximately 6.5 days; a study during Delta predominance reported approximately 4.3 days, while studies during Omicron predominance found median intervals of about 3–4 days. These estimates describe populations, not a fixed timetable for every infection, and means and medians are not directly interchangeable. Infectiousness is concentrated around symptom onset: transmission commonly occurs during the preceding 1–2 days and the first few symptomatic days, although infectiousness can persist beyond that interval. (cdc.gov)
Presymptomatic transmission occurs before symptoms develop, whereas asymptomatic transmission originates from people who remain without symptoms throughout infection. Both occur with SARS-CoV-2, making symptom-based detection alone insufficient to identify every infectious person. In an influential April 2020 study, Xi He and colleagues examined viral shedding in 94 patients and reconstructed infectiousness from 77 infector–infectee pairs. They inferred that infectiousness peaked on or before symptom onset and estimated that 44% of secondary infections occurred during the source patient’s presymptomatic stage. That estimate concerned particular early-pandemic settings with substantial household clustering and active case finding, rather than a universal proportion. Transmission before illness becomes apparent limits the effectiveness of isolation initiated only after symptoms begin and complicates contact tracing. (cdc.gov)
Transmission is highly uneven: many infected people generate no detected secondary cases, while a minority generate numerous infections in superspreading events. Dillon C. Adam and colleagues analysed 1,038 confirmed cases in Hong Kong between 23 January and 28 April 2020. Their reconstruction estimated that 19% of cases accounted for 80% of local transmission; social settings were associated with more secondary cases than households. These findings illustrate transmission heterogeneity rather than an invariant “80/20 rule” applying to every variant or population. (nature.com)
A well-documented indoor example occurred at a choir rehearsal in Skagit County, Washington, on 10 March 2020. Sixty-one people attended the 2.5-hour practice, including a symptomatic index patient. Investigators subsequently identified 32 laboratory-confirmed and 20 probable secondary cases: secondary attack rates of 53.3% when counting confirmed cases alone and 86.7% when including probable cases. Close spacing and sustained singing provided conditions favourable to transmission. The investigation implicated respiratory exposure, including possible aerosol emission during singing, but could not assign every infection to a single route because participants also shared snacks and handled chairs. (cdc.gov)
Clinical features and disease course
COVID-19 ranges from asymptomatic infection to critical illness. Mild symptomatic disease commonly involves fever, cough, sore throat, nasal congestion, headache, muscle aches and fatigue; nausea, vomiting or diarrhoea may occur, sometimes before respiratory symptoms. Fever is not invariably present at the beginning of illness, and older adults may have atypical presentations. Lower respiratory involvement produces pneumonia, breathlessness and hypoxaemia—abnormally low blood oxygen. Symptoms overlap with those of other respiratory infections and do not, by themselves, establish the diagnosis. Chest imaging in severe disease may show bilateral, peripheral ground-glass opacities or consolidation. Clinical severity classifications commonly distinguish mild-to-moderate illness without an oxygen requirement from severe illness with room-air oxygen saturation below 94% at sea level or a need for supplemental oxygen. (archive.cdc.gov)
New loss of smell, termed anosmia, and loss of taste were distinctive features of early pandemic presentations, although they were not universal. Their frequency declined substantially with Omicron. In a 2022 prospective observational study, Cristina Menni and colleagues compared two matched groups of 4,990 symptomatic UK participants who had received at least two vaccine doses. Reported smell loss occurred in 52.7% during Delta predominance, between June and November 2021, compared with 16.7% during Omicron predominance, between December 2021 and January 2022. Conversely, sore throat was reported by 60.8% and 70.5%, respectively. These estimates describe vaccinated, symptomatic app users rather than all infections; variant assignment was based on periods of predominance, not individual sequencing in every participant. (discovery.ucl.ac.uk)
Deterioration can follow an initially mild presentation. Early studies of severe cases in Wuhan reported median intervals of 5–8 days from symptom onset to breathlessness and 8–12 days to acute respiratory distress syndrome (ARDS). These historical intervals describe particular early cohorts, not a fixed timetable for every infection. Critical illness includes respiratory failure, shock and multiorgan dysfunction. Associated complications include acute kidney injury, cardiomyopathy, arrhythmias, venous thromboembolism and stroke; secondary infections may complicate prolonged hospitalization. Hypoxaemia and systemic inflammation can contribute to activation of coagulation pathways, linking respiratory disease with vascular complications. (archive.cdc.gov) In a 2020 autopsy study, Maximilian Ackermann and colleagues documented severe pulmonary endothelial injury and widespread microvascular thrombosis, providing pathological evidence of vascular involvement alongside lung injury. (nejm.org)
Age is the strongest established risk factor for severe outcomes, with risk increasing markedly in older age groups. Other associated conditions include obesity, diabetes mellitus, cardiovascular disease, chronic kidney disease and chronic lung disease; having several underlying conditions further increases risk. Immunosuppression—including that associated with transplantation, certain cancers, primary immune deficiencies or immunosuppressive medication—is also associated with severe disease. Vaccination status modifies risk, so estimates from unvaccinated populations early in 2020 are not directly interchangeable with those from later populations. Children generally have milder acute illness than adults, but severe disease can occur, particularly with underlying medical conditions. (cdc.gov)
Pregnancy is independently associated with increased risk of severe COVID-19. A US surveillance analysis covering January 22–October 3, 2020 compared symptomatic women aged 15–44 years with laboratory-confirmed infection. Intensive-care admission occurred in 10.5 per 1,000 pregnant cases versus 3.9 per 1,000 nonpregnant cases; after adjustment for age, race or ethnicity and underlying conditions, the risk ratio was 3.0. Invasive ventilation occurred in 2.9 versus 1.1 per 1,000 cases, with an adjusted risk ratio of 2.9. These pre-vaccine observations establish pregnancy as a risk factor while describing absolute risks in a specific surveillance population and period. (cdc.gov)
Pathogenesis and the immune response
SARS-CoV-2 infects susceptible epithelial cells after its spike protein binds ACE2 and is activated by host proteases, including TMPRSS2 or endosomal cathepsins. Experiments reported by Markus Hoffmann and colleagues in 2020 established the roles of ACE2 and TMPRSS2 in entry. In human airway cultures, the virus replicates in ciliated and secretory cells, producing double-membrane vesicles that accommodate its replication machinery. Its positive-sense RNA is translated into viral proteins, including the enzymes required to copy the genome and produce subgenomic messenger RNAs. Infection disrupts epithelial architecture and damages cilia, impairing the airway’s capacity to clear mucus and inhaled particles. (pubmed.ncbi.nlm.nih.gov)
In fatal disease, lung tissue shows both viral injury and extensive changes in the host cellular response. A 2021 single-cell autopsy atlas identified depletion of alveolar epithelial cells, inflammatory immune-cell infiltration and abnormal repair programmes. Vascular injury is another important component: Maximilian Ackermann and colleagues’ 2020 comparison of seven COVID-19 lungs with seven influenza lungs found alveolar-capillary microthrombi nine times as prevalent in the COVID-19 specimens. Infection can also extend beyond the respiratory tract. Sydney Stein and colleagues’ 2022 autopsy study detected viral replication in several non-respiratory tissues, including the brain, early in infection. Nevertheless, widespread viral RNA was accompanied by relatively little direct cytopathology outside the respiratory tract; detecting viral material in an organ does not, by itself, establish that direct infection caused its dysfunction. (nature.com)
Innate immunity begins with cellular recognition of infection. Experiments in lung epithelial cells identified MDA5 as a major sensor driving type I and type III interferon production after SARS-CoV-2 replication. Interferons activate antiviral gene-expression programmes in infected and neighbouring cells. Severe disease can combine inadequate antiviral signalling with substantial inflammation: Jérôme Hadjadj and colleagues’ 2020 study of 50 patients found severely impaired type I interferon activity in severe and critical cases, alongside increased interleukin-6 and tumour necrosis factor signalling. This pattern distinguishes failure to control viral replication from failure to mount an inflammatory response; the two can occur simultaneously. (nature.com)
The virus interferes with these defences through several molecular mechanisms. Structural experiments published in 2020 showed that its non-structural protein NSP1 inserts into the messenger-RNA entry channel of the host ribosome’s 40S subunit, inhibiting host protein synthesis. A separate 2021 study demonstrated that the viral papain-like protease removes ISG15 modifications from MDA5, antagonizing activation of this antiviral sensor. Host factors can also undermine interferon defence. Paul Bastard and colleagues reported in 2020 that 101 of 987 patients with life-threatening COVID-19 pneumonia—10.2% of that cohort—had autoantibodies capable of neutralizing interferon-α, interferon-ω or both. These findings identify distinct routes to impaired antiviral immunity rather than a single mechanism shared by all critically ill patients. (nature.com)
Adaptive immunity provides antigen-specific responses through B cells and T cells. Neutralizing antibodies can prevent viral entry, while CD4-positive T cells support antibody production and coordinate immune responses; CD8-positive T cells recognize and eliminate infected cells. These responses also establish immunological memory. Jennifer Dan and colleagues’ 2021 study analysed 254 samples from 188 recovered individuals, including samples collected six to eight months after infection. Spike-specific memory B cells were more abundant at six months than at one month, while antibody, CD4-positive T-cell and CD8-positive T-cell responses followed different trajectories. Consequently, declining circulating antibody concentrations do not necessarily signify disappearance of immune memory, and a single antibody measurement does not capture the full adaptive response. (pmc.ncbi.nlm.nih.gov)
Critically ill patients can nevertheless display ineffective viral clearance alongside damaging immune activation. The 2021 tissue atlas documented extensive inflammatory macrophage accumulation, altered epithelial repair and pathological fibroblast populations in affected lungs. Together with the impaired interferon activity and increased inflammatory cytokine signalling observed in severe cases, these findings show how antiviral defence, inflammatory injury and tissue repair become uncoupled. The resulting pathology is therefore not explained solely by viral abundance or by a uniform “cytokine storm”: disrupted immune regulation and failure to restore the alveolar barrier are also central features of severe pulmonary disease. (nature.com)
Long COVID (post-COVID-19 condition)
Long COVID encompasses persistent or newly developing health problems following SARS-CoV-2 infection. The World Health Organization (WHO) clinical definition, published on 6 October 2021, describes post-COVID-19 condition in people with probable or confirmed infection, usually three months after illness onset, with symptoms lasting at least two months that cannot be explained by another diagnosis. Symptoms may continue from the acute illness, emerge after apparent recovery, or fluctuate and relapse. The condition is not restricted to people who were hospitalized: it can also follow an initially asymptomatic infection. (who.int)
Common manifestations include fatigue, breathlessness, cognitive difficulties—often called “brain fog”—and reduced exercise tolerance. Cognitive complaints may involve concentration, memory and the ability to perform everyday tasks. A distinctive feature in some patients is post-exertional malaise, also termed post-exertional symptom exacerbation: minor physical or mental effort can trigger worsening symptoms, typically after a delay of 12–48 hours, lasting days or weeks. This differs from ordinary tiredness immediately after activity. Clinical assessment relies on the history, examination and investigations directed at particular symptoms; no laboratory test definitively establishes or excludes long COVID, and normal routine findings do not negate functional impairment. (who.int)
Several overlapping biological mechanisms are under investigation. Persistent viral reservoirs or retained viral components could sustain immune stimulation; autoimmunity could arise through responses directed against host tissues; and prolonged immune dysregulation could maintain inflammation after the initial infection. Vascular hypotheses involve endothelial injury, platelet activation and disturbed clotting, potentially impairing microvascular function. These remain proposed mechanisms rather than a single established explanation. In a 2024 study, Carlo Cervia-Hasler and colleagues followed patients for up to 12 months and identified blood-protein patterns associated with active long COVID, including complement-system activation, altered coagulation and markers of tissue injury. Such associations support investigation of immune–vascular pathways but do not by themselves establish causation or provide a validated diagnostic biomarker. (cdn.who.int)
Risk estimates vary with the population, follow-up period and definition used. A 2024 US Veterans Affairs study included 441,583 infected veterans and 4,748,504 uninfected controls. Among unvaccinated participants, the estimated cumulative incidence of postacute sequelae during the first year was 10.42 per 100 people in the pre-Delta era, 9.51 in the Delta era and 7.76 in the Omicron era. Among vaccinated participants infected during the Omicron era, it was 3.50 per 100. These estimates concern a broad set of postacute outcomes in a veteran population, not a universal prevalence of WHO-defined post-COVID-19 condition. Era comparisons also combine changes in viral characteristics with vaccination and other temporal influences. (nejm.org)
Meta-analytic evidence likewise associates vaccination before infection with lower risk, without complete protection. A 2023 analysis pooling 21 observational studies of vaccination before infection reported an odds ratio of 0.631 (95% confidence interval, 0.518–0.769) for post-COVID conditions among fully vaccinated versus unvaccinated people. Its definition included symptoms persisting for at least four weeks, illustrating why estimates cannot be directly equated with studies using a three-month threshold. Differences in case ascertainment, vaccine doses and participant characteristics complicate comparisons; observational associations are not equivalent to randomized estimates of a causal effect. (pmc.ncbi.nlm.nih.gov)
Long-term care generally focuses on symptom management, functional goals and individualized rehabilitation. Activity management, including pacing, seeks to balance activity and rest where exertion precipitates relapses; rehabilitation protocols distinguish this presentation from patients able to tolerate progressive activity. The 2024 REGAIN randomized controlled trial enrolled 585 adults with continuing problems after COVID-19 hospitalization and found improved health-related quality of life with an eight-week online programme combining supervised physical rehabilitation and psychological support. Its findings apply to the studied post-hospital population rather than every long-COVID presentation. Fluctuating symptoms, the absence of a definitive diagnostic test and the need to coordinate care across different symptom domains complicate follow-up and assessment of treatment response. (iris.who.int)
Diagnosis and laboratory testing
Reverse transcription polymerase chain reaction (RT-PCR), a nucleic acid amplification test, is the reference laboratory method for detecting SARS-CoV-2 infection. Viral RNA extracted from a respiratory specimen is converted into complementary DNA; selected sequences are then amplified and detected, usually through fluorescent probes in real-time assays. Tests target regions such as the envelope, nucleocapsid or RNA-dependent RNA polymerase genes. Unlike serological testing, which measures the host response, RT-PCR directly detects viral genetic material. Its high analytical sensitivity allows detection of small quantities of RNA, but clinical performance also depends on specimen collection, sampling site and timing. (who.int)
RT-PCR sensitivity changes over the course of infection, rather than having a single value applicable to every patient. In a 2020 pooled analysis of seven studies involving 1,330 upper-respiratory samples, Lauren Kucirka and colleagues estimated a false-negative probability of 38% on the modeled day of symptom onset, falling to 20% three days later before increasing again. These estimates described early-pandemic datasets, not universal performance figures for subsequent assays or variants. Conversely, RNA may remain detectable for up to 90 days after infection, including after the period of transmissibility has passed. A positive molecular result therefore does not, by itself, demonstrate the presence of replication-competent virus. (doi.org)
Rapid antigen tests detect viral proteins in respiratory specimens, commonly using lateral-flow immunoassays. They provide results within minutes, require less equipment than laboratory RT-PCR and enabled widespread home testing. Their specificity is generally high, but their sensitivity is lower, particularly when viral concentrations are low or symptoms are absent. In a US household study conducted from November 2022 to May 2023 and published in 2024, daily antigen-test sensitivity was 47% against same-day RT-PCR and 80% against viral culture. These different values reflect different reference standards: RNA detection and recovery of viable virus are not equivalent, and culture itself is not an absolute measure of transmissibility. In November 2022, the US Food and Drug Administration required updated labeling for emergency-authorized antigen tests to incorporate repeat testing after negative results: at least two tests 48 hours apart for symptomatic users, or three at 48-hour intervals for asymptomatic users. (who.int)
Serological assays detect antibodies in blood and are principally used to investigate previous infection and population exposure, rather than diagnose acute infection. Measurable antibodies typically begin to appear 7–14 days after illness onset; some infected people do not develop detectable responses, while antibodies may later decline below assay thresholds. Anti-spike antibodies can follow either infection or spike-based vaccination. Anti-nucleocapsid antibodies distinguish infection from the effects of the spike-based vaccines used in the United States. A CDC survey of residual clinical specimens estimated that infection-induced antibody seroprevalence increased from 33.5% in December 2021 to 57.7% in February 2022. Such surveys capture infections missed by routine diagnostic reporting, although antibody waning and specimen-selection biases limit interpretation. Antibody results are not an established individual measure of protection against subsequent infection or severe disease. (archive.cdc.gov)
Genomic surveillance complements diagnostic testing by sequencing viral material from selected positive specimens and identifying combinations of mutations that define lineages. In the United States, CDC surveillance combined the National SARS-CoV-2 Strain Surveillance system, commercial laboratories and sequences deposited in public repositories, with statistical weighting used to estimate circulating lineage proportions. Sequencing usually serves population surveillance rather than routine individual diagnosis. Its coverage depends on access to suitable specimens: the median weekly number of sequences in the US surveillance dataset declined from 21,905 in 2022 to 4,752 in 2023 and 1,989 in 2024. CDC identified reduced laboratory testing and increased home testing as constraints on specimen availability and surveillance sensitivity. (cdc.gov)
Testing capacity also constrained detection during surges. A laboratory survey presented at a CDC response call in June 2020 documented supply-chain limitations and turnaround times predominantly of 12–24 or 24–48 hours. In September 2021, CDC issued a laboratory advisory about shortages of rapid tests and the resulting pressure on laboratory-based testing. These operational constraints meant that analytical accuracy alone could not determine the usefulness of a testing system: access, supplies and timely reporting also affected which infections were detected and how quickly results became available. (cdc.gov)
Variants and viral evolution
An early consequential mutation was D614G, which replaces aspartic acid with glycine at position 614 of the spike protein. It spread widely during 2020 and became incorporated into subsequent major variants. Experiments with otherwise genetically identical viruses showed that D614G increased virion infectivity and stability, enhanced replication in human airway tissues, and improved transmission in animal models. These findings provided experimental support for a transmission advantage rather than merely an association between a mutation and expanding outbreaks. D614G also illustrates why individual substitutions must be investigated experimentally: their effects depend on protein structure and the surrounding viral genetic background. (nature.com)
The World Health Organization (WHO) introduced Greek-letter labels on 31 May 2021, alongside scientific lineage names. Its historical tables identify the earliest documented samples of Alpha (B.1.1.7) in the United Kingdom in September 2020, Beta (B.1.351) in South Africa in May 2020, Gamma (P.1) in Brazil in November 2020, and Delta (B.1.617.2) in India in October 2020; these sampling locations do not establish where each lineage originated. All four became variants of concern. Alpha’s N501Y spike substitution increased receptor binding and contributed substantially to enhanced transmission in experimental studies. Beta and Gamma carried E484K, which reduced recognition by some neutralizing antibodies, demonstrating that viral evolution could affect immune recognition as well as infectivity. (emro.who.int)
Delta combined efficient replication with partial immune evasion and displaced Alpha in many settings during 2021. Its characteristic spike substitutions included L452R, T478K and P681R. In a study published in Nature in 2021, Delta replicated more efficiently than Alpha in airway organoids and human airway epithelial cultures, and its spike protein was more extensively cleaved, facilitating cell entry and fusion. In the same experiments, Delta was approximately sixfold less sensitive to neutralization by sera from recovered individuals and eightfold less sensitive to vaccine-elicited antibodies than the ancestral comparator carrying D614G. These laboratory ratios describe particular assays and serum samples, not equivalent reductions in clinical vaccine protection. (nature.com)
Omicron (B.1.1.529), reported from South Africa in November 2021, was designated a variant of concern on 26 November. WHO’s early assessments counted 26–32 spike mutations across its initial lineages, an unusually large divergence affecting both immune recognition and transmission. BA.1 and BA.2 spread rapidly, followed by additional branches including BA.4 and BA.5. Although early Omicron infections had a lower observed risk of severe disease than infections with preceding variants, exceptionally high transmission still produced substantial hospital burdens. Genetic recombination also generated new lineages: XBB, identified in 2022, combined genetic material from the BA.2.10.1 and BA.2.75 branches rather than arising solely through successive mutations within one lineage. (who.int)
JN.1 descended from BA.2.86 and carried the additional spike substitution L455S; WHO classified it separately as a variant of interest on 19 December 2023. Later JN.1-derived branches included KP.3.1.1, LP.8.1, NB.1.8.1 and XFG. WHO designated NB.1.8.1 a variant under monitoring on 23 May 2025 and XFG on 25 June 2025. XFG is a recombinant of LF.7 and LP.8.1.2. In WHO’s June 2025 assessment, its share of submitted global sequences increased from 7.4% to 22.7% between epidemiological weeks 19 and 22. That assessment found no indication of greater disease severity than other circulating variants, distinguishing rapid expansion from increased virulence. (who.int)
WHO revised its classification framework on 15 March 2023 to assess Omicron sublineages independently. Variants under monitoring warrant prioritized investigation because their changes may pose additional risks. Variants of interest have relevant genetic changes and an epidemiological growth advantage or other evidence suggesting an emerging public-health risk. Under the revised framework, a variant of concern additionally shows increased disease severity, a substantial health-system impact requiring major interventions, or a significant reduction in vaccine protection against severe disease. Classification therefore combines genetic, laboratory and epidemiological evidence; a large mutation count or increasing frequency alone does not establish that a lineage is more dangerous. (who.int)
Vaccines and vaccination
Four major vaccine platforms were used during the pandemic. Pfizer–BioNTech’s BNT162b2 and Moderna’s mRNA-1273 deliver messenger RNA encoding the SARS-CoV-2 spike protein, which recipient cells produce as an antigen. Adenoviral-vector vaccines, including Oxford–AstraZeneca’s ChAdOx1 and Janssen’s Ad26.COV2.S, use modified, non-replicating adenoviruses to carry genetic instructions for spike production. Inactivated-virus vaccines, including Sinovac’s CoronaVac and Sinopharm’s BBIBP-CorV, contain whole virus rendered non-infectious. Protein-subunit vaccines, such as Novavax’s NVX-CoV2373, supply manufactured viral protein rather than instructions for producing it, generally with an adjuvant that strengthens the immune response. These approaches expose the immune system to viral antigens without causing SARS-CoV-2 infection. (who.int)
Vaccine efficacy in a randomized controlled trial measures the relative reduction in a specified outcome compared with a control group; effectiveness measures protection under routine conditions. In the initial 2020 trials, two doses of BNT162b2 had 95.0% efficacy against symptomatic COVID-19, with eight cases in vaccine recipients versus 162 in placebo recipients, while mRNA-1273 had 94.1% efficacy. These estimates concerned symptomatic disease during the trial period, not permanent protection or prevention of every infection. (nejm.org) Protection also differed by outcome. A national Chilean cohort of approximately 10.2 million people studied between February and May 2021 estimated two-dose CoronaVac effectiveness at 65.9% against COVID-19, 87.5% against hospitalization, 90.3% against intensive-care admission and 86.3% against COVID-19-related death. Such estimates cannot serve as direct rankings of platforms because populations, circulating variants and study designs differed. (nejm.org)
Viral evolution and time since vaccination altered protection, particularly against infection and symptomatic illness. In an English study published in 2022, Nick Andrews and colleagues found that effectiveness against symptomatic Omicron infection after two BNT162b2 doses declined from 65.5% at two to four weeks to 8.8% at 25 weeks or more. A BNT162b2 booster raised effectiveness to 67.2% at two to four weeks, followed by a decline to 45.7% at ten weeks or more. (nejm.org) Breakthrough infections therefore became common without implying that vaccination provided no benefit: protection against serious illness and death remained more substantial than protection against infection, although it also waned. Immunity from both vaccination and previous infection, termed hybrid immunity, provided more durable protection against severe outcomes than infection alone. (who.int)
Booster programmes were followed by updated seasonal formulations intended to improve recognition of circulating variants. United States programmes progressed from ancestral-strain vaccines to ancestral–Omicron bivalent formulations in 2022, monovalent XBB.1.5 vaccines in 2023, and JN.1-lineage formulations in 2024. (cdc.gov) In surveillance covering September 2024–January 2025, the 2024–2025 vaccine provided an estimated 33% additional protection against emergency-department or urgent-care visits in adults and 45–46% against hospitalization in immunocompetent adults aged at least 65 years during the first 7–119 days after vaccination. The comparator was people who had not received that season’s vaccine, rather than necessarily people never vaccinated. (cdc.gov) On 16 May 2026, the World Health Organization retained monovalent LP.8.1 as its recommended vaccine antigen, while allowing alternatives demonstrating broad neutralizing responses or efficacy against circulating variants. (who.int)
Rollout initially prioritized groups with high exposure or high risks of severe disease. WHO’s European advisory group specified health workers at risk, older adults and long-term-care residents as priorities in November 2020, when initial supplies were expected to cover only 1–10% of national populations. (who.int) Coverage subsequently diverged sharply between countries: on 20 May 2022, WHO reported that only 16% of people in low-income countries had received at least one dose, compared with 80% in high-income countries. COVAX pooled procurement and supplied donor-funded doses, but improving supply did not eliminate delivery constraints; financing, workforce capacity, demand and uptake remained obstacles. Some supported countries, including Bhutan, Cambodia and Bangladesh, nevertheless exceeded 70% coverage, illustrating variation within income groups. (who.int)
Treatment and clinical management
Antiviral treatment is principally directed at early infection in people at increased risk of hospitalization or death. Nirmatrelvir–ritonavir is an oral, five-day treatment begun within five days of symptom onset. Nirmatrelvir inhibits the viral main protease, preventing processing of proteins required for replication; ritonavir slows its metabolism, maintaining effective drug concentrations but also creating important drug interactions. In the EPIC-HR randomized controlled trial, published in 2022, unvaccinated, high-risk adults treated within three days had a hospitalization-or-death rate of 0.77%, compared with 7.01% with placebo in the interim analysis. These results concern a particular population and do not establish an equivalent absolute benefit in vaccinated or lower-risk patients. Treatment selection takes account of concurrent medicines and renal and hepatic function. (nejm.org)
Remdesivir inhibits the viral RNA-dependent RNA polymerase. Initially used in hospitalized patients, it shortened median recovery time from 15 to 10 days in the 1,062-patient ACTT-1 trial reported in 2020. Its outpatient regimen consists of intravenous infusions on three consecutive days, started within seven days of symptom onset; a trial in unvaccinated, high-risk outpatients found an 87% relative reduction in hospitalization or death. Molnupiravir, another oral antiviral, introduces errors into newly synthesized viral RNA. Its five-day course, begun within five days, has been used in high-risk adults when preferred treatments were unavailable or unsuitable. Its lower efficacy and reproductive safety concerns limited its role, and it is avoided during pregnancy. (nejm.org)
For hospitalized patients requiring supplemental oxygen, treatment also targets damaging inflammation. The British RECOVERY trial, reported in 2020, compared dexamethasone at 6 mg daily for up to ten days with usual care: 2,104 patients received dexamethasone and 4,321 received usual care. Twenty-eight-day mortality was 29.3% versus 41.4% among patients receiving invasive ventilation, and 23.3% versus 26.2% among those receiving oxygen without invasive ventilation. There was no demonstrated benefit in patients receiving no respiratory support. These findings established systemic corticosteroids as treatment for severe or critical disease rather than uncomplicated infection. Additional immunomodulation with tocilizumab, which blocks the interleukin-6 receptor, or baricitinib, a Janus kinase inhibitor, has been incorporated into care for selected patients with progressive severe disease despite corticosteroid treatment. (nejm.org)
Neutralizing monoclonal antibodies bind specific sites on the viral spike protein, but their activity depends on the infecting variant retaining those sites. Products including casirivimab–imdevimab, sotrovimab and bebtelovimab consequently lost their treatment roles as resistant variants spread. Bebtelovimab ceased to be authorized for use in any United States region on November 30, 2022, because of resistance in Omicron subvariants BQ.1 and BQ.1.1. On December 13, 2024, the Food and Drug Administration formally revoked four antibody-product emergency authorizations at the sponsors’ requests. This withdrawal concerned particular products, not the antibody platform generally; anti-inflammatory antibodies such as tocilizumab act on host signalling rather than directly neutralizing the virus. (idsociety.org)
Respiratory support ranges from supplemental oxygen to high-flow nasal oxygen, non-invasive ventilation and invasive mechanical ventilation, according to hypoxaemia and respiratory failure. Prone positioning places patients face down and is used in both ventilated patients and selected awake patients receiving oxygen or non-invasive support. The World Health Organization conditionally recommended awake prone positioning in this latter group in its 2023 clinical-management guideline. Hospital care also includes prevention of venous thromboembolism. Anticoagulation intensity depends on illness severity, established indications and bleeding risk: the 2021 multiplatform heparin trials found improved survival to discharge without organ support in noncritically ill patients receiving therapeutic dosing, but no corresponding benefit in critically ill patients, making routine escalation to full-dose anticoagulation inappropriate across all hospitalized groups. (who.int)
Public health measures and non-pharmaceutical interventions
Public health measures distinguished isolation, the separation of infected people from others, from quarantine, which restricted the contacts of exposed people who might become infectious. Contact tracing identified exposures, notified contacts, and linked them to testing and quarantine; its purpose was to interrupt transmission before further infections occurred. Early World Health Organization (WHO) guidance recommended quarantine for 14 days after the last exposure. This approach addressed transmission before symptom onset, which made symptom screening alone insufficient. Its effectiveness depended on rapid case detection and notification, compliance, and practical support for people staying apart from others. (who.int)
National strategies combined these tools differently. South Korea deployed extensive testing and contact investigation: Young Joon Park and colleagues analysed 59,073 contacts of 5,706 index patients identified between 20 January and 27 March 2020, illustrating the scale of its tracing operation. New Zealand pursued elimination through border restrictions, 14-day quarantine for returning travellers, widespread testing, case isolation, contact tracing, and population-wide restrictions. Its highest alert level began on 25 March 2020, closing non-essential services and restricting movement. These were packages of mutually reinforcing interventions, rather than evidence that testing, border controls, or lockdowns alone could achieve elimination. (stacks.cdc.gov)
Masks reduced exposure by filtering respiratory particles, with performance dependent on fit, filtration, and consistent use. They were combined with physical distancing, avoidance of crowded indoor spaces, and ventilation, which diluted potentially infectious indoor air. (who.int) A cluster-randomized trial led by Jason Abaluck, conducted from November 2020 to April 2021 across 600 Bangladeshi villages and 342,183 adults, tested free mask distribution and promotion. Proper mask use increased from 13.3% in control villages to 42.3% in intervention villages; symptomatic SARS-CoV-2 seroprevalence was approximately 9% lower in the intervention group. This estimated the effect of a community promotion programme, not the intrinsic filtration efficiency of masks or the effect of universal adherence. (pubmed.ncbi.nlm.nih.gov)
Gathering limits, school and business closures, and stay-at-home orders reduced opportunities for interpersonal contact. In a 2021 analysis of 41 countries, Jan M. Brauner and colleagues used a Bayesian transmission model to estimate the effects of first-wave restrictions. Limiting gatherings to ten people or fewer, closing schools and universities together, and closing face-to-face businesses were associated with substantial transmission reductions; stay-at-home orders added comparatively little when those measures were already operating. The estimates were context-dependent, and the study could not separate school closures from university closures reliably. Simultaneous interventions and changes in voluntary behaviour complicated attribution of effects to individual policies. (pmc.ncbi.nlm.nih.gov)
The feasibility of restrictions depended partly on their social and economic costs. In 37 UK surveys covering March 2020–January 2021, Louise E. Smith and colleagues estimated duration-adjusted adherence to complete self-isolation among symptomatic respondents at 42.5%; financial hardship and lower socioeconomic status were associated with poorer adherence. (bmj.com) School closures disrupted education for more than 1.6 billion learners in over 190 countries at the 2020 peak, with disadvantaged learners particularly affected. Educational disruption, isolation, and reduced social contact also created psychological burdens, although these overlapped with the effects of illness and wider pandemic uncertainty. (unesco.org)
Guidance subsequently shifted towards targeted, longer-term management. On 24 February 2022, England ended the legal requirement to self-isolate following a positive test and discontinued routine contact tracing. (gov.uk) WHO’s guidance of 6 July 2022 prioritized tracing and quarantine for exposed people at high risk rather than all contacts, citing increasing population immunity, and allowed shorter quarantine through testing. (who.int) On 1 March 2024, the US Centers for Disease Control and Prevention replaced its fixed COVID-19 community isolation period with unified respiratory-virus guidance: return to normal activities followed at least 24 hours of overall symptom improvement and absence of fever without fever-reducing medication, followed by five days of additional precautions. Separate guidance remained applicable to healthcare settings. (cdc.gov)
Epidemiology and global burden
As of 28 June 2026, more than 779 million confirmed COVID-19 cases and over seven million confirmed deaths had been reported globally to the World Health Organization (WHO). These cumulative surveillance totals substantially underestimate infections and reinfections. They also become less comparable over time as countries reduce testing and discontinue comprehensive case reporting. WHO increasingly monitors circulation through sentinel respiratory surveillance, including the proportion of systematically collected samples testing positive for SARS-CoV-2, rather than relying exclusively on notified case counts. A fall in reported cases therefore does not necessarily represent an equivalent fall in incidence. (who.int)
Population-based seroprevalence surveys measure antibodies in sampled populations and reveal exposure missed by routine testing. Estimates summarized by WHO indicated that global seropositivity rose from approximately 16% in February 2021 to 67% in October 2021. This was not equivalent to the percentage previously infected: vaccination also produces detectable antibodies. Interpretation depends on vaccine platform and assay target; antibodies against nucleocapsid can indicate infection after spike-only vaccines, but inactivated whole-virus vaccines can also induce them. Serological results do not enumerate repeated infections, and seropositivity alone cannot establish the degree of protection against future infection. In many low- and middle-income countries, the increase during 2021 was predominantly infection-driven because vaccination coverage remained low. (who.int)
Excess mortality provides a broader measure of the pandemic’s lethal burden by comparing observed all-cause deaths with deaths expected from pre-pandemic trends. WHO estimated approximately 14.9 million excess deaths worldwide during 2020–2021, with an uncertainty interval of 13.3–16.6 million—about 9.5 million more than the COVID-19 deaths officially reported for that period. This measure includes unrecognized deaths directly caused by infection and indirect deaths associated with disrupted access to treatment; it is also affected by reductions in other causes, such as road injuries. Consequently, it is not simply a corrected count of deaths caused by the virus. Approximately 84% of WHO’s estimated excess deaths occurred in South-East Asia, Europe and the Americas, and 81% occurred in middle-income countries. Absolute totals reflect population size as well as mortality risk. (who.int)
Mortality risk varies sharply with age. A 2020 systematic review and meta-analysis led by Andrew T. Levin estimated an infection fatality ratio—the proportion of all infected people who die—of approximately 0.01% at age 25, 1.4% at age 65 and 15% at age 85. These estimates describe early, pre-vaccination conditions rather than fixed risks across subsequent variants and immune histories. The analysis found that much of the variation between population-level fatality estimates reflected population age structures and the ages of those infected. WHO’s excess-mortality estimates likewise showed a greater burden among older adults and a sex distribution of approximately 57% male and 43% female. (pmc.ncbi.nlm.nih.gov)
The capacity of a health system influences outcomes during concentrated infection waves. A United States analysis using data from July 2020 to July 2021 found an association between intensive-care occupancy and subsequent excess deaths. Its model estimated that nationwide occupancy of 75% would be associated with roughly 12,000 additional excess deaths two weeks later. Occupancy was a marker of broader system strain, not proof that bed utilization itself caused those deaths. The early Omicron wave illustrated how lower severity per case could coexist with substantial population burden: United States surveillance found lower hospitalization-to-case and death-to-case ratios than during earlier high-transmission periods, but very high infection numbers still strained services. (cdc.gov)
Successive waves differed in timing and magnitude across regions. During 17–23 January 2022, amid Omicron’s expansion, WHO recorded more than 21 million new cases worldwide, then the highest reported weekly total. Later circulation increasingly resembled persistent, endemic transmission with periodic epidemics rather than uninterrupted emergency-level spread. This did not establish a uniform global seasonal pattern: a 2025 United States study documented year-round circulation with recurrent late-summer and winter peaks. WHO continued to report global circulation and severe outcomes in 2026, while the declining completeness of notification made later waves harder to compare directly with those captured by early-pandemic mass testing. (who.int)
Timeline of the pandemic and international declarations
On 31 December 2019, the World Health Organization (WHO) country office in China became aware of a Wuhan Municipal Health Commission statement describing cases of pneumonia of unknown cause. WHO activated its incident-management support system on 1 January 2020 and published its first Disease Outbreak News report on 5 January. Chinese authorities identified a novel coronavirus, and its genetic sequence became publicly available in January, enabling laboratories to develop diagnostic tests. These events initiated international surveillance and technical coordination before the outbreak received formal emergency status. (who.int)
On 30 January 2020, WHO Director-General Tedros Adhanom Ghebreyesus declared a public health emergency of international concern (PHEIC), accepting the advice of an Emergency Committee convened under the International Health Regulations (2005). The declaration provided the framework for temporary recommendations to countries on surveillance, detection, containment and information sharing. WHO announced the disease name COVID-19 on 11 February. On 11 March, it characterized the outbreak as a pandemic; its situation report that day recorded 118,319 confirmed cases and 4,292 deaths worldwide. The pandemic characterization described the outbreak’s global spread, whereas the PHEIC was its formal emergency designation under international law. (who.int)
International coordination expanded through operational and financing mechanisms. WHO’s Strategic Preparedness and Response Plan, finalized on 3 February 2020, guided national preparedness, international coordination and research priorities. Its situation reports compiled country notifications into a shared account of geographic spread and response requirements. On 24 April, WHO, the European Commission, France and the Bill & Melinda Gates Foundation launched the Access to COVID-19 Tools Accelerator to coordinate the development and availability of tests, treatments and vaccines. On 31 December, WHO issued its first COVID-19 vaccine emergency-use listing, for Pfizer–BioNTech’s Comirnaty; this enabled countries to expedite regulatory assessments and allowed UNICEF and the Pan American Health Organization to procure it for distribution. (who.int)
National policies shifted away from emergency restrictions on different schedules. In England, the legal requirement to self-isolate after a positive test ended on 24 February 2022, alongside routine contact tracing; guidance to stay at home when infected remained. Free testing for the general public ended on 1 April, with provision retained for specified groups. These changes applied to England rather than uniformly across the United Kingdom. In the United States, the federal public-health emergency declared on 31 January 2020 expired on 11 May 2023 after 13 renewals. Its expiration ended certain federal data-collection authorities and prompted changes in national reporting, while hospitalization, mortality, emergency-department and wastewater surveillance continued. (gov.uk)
On 5 May 2023, Tedros accepted the recommendation of the fifteenth Emergency Committee meeting, chaired by Didier Houssin, and determined that COVID-19 no longer constituted a PHEIC. The committee cited declining deaths, hospitalizations and intensive-care admissions, together with high population immunity. The decision did not signify that SARS-CoV-2 transmission had stopped or that COVID-19 had ceased to pose a global health threat. WHO instead described a transition to long-term management of an established, ongoing health issue. Its accompanying recommendations called for integrating vaccination into routine programmes, maintaining reporting of illness, deaths and variants, and combining sentinel, wastewater and other surveillance systems rather than dismantling response capacity. (who.int)
Economic and social consequences
COVID-19 produced a global recession through overlapping shocks to production, consumption and investment. Illness, workplace closures and transport restrictions reduced productive capacity, while infection concerns and restrictions on face-to-face activity depressed spending on hospitality, entertainment and travel. In April 2021, the International Monetary Fund estimated that global real gross domestic product had contracted by 3.3% in 2020. Recovery differed substantially between countries: access to vaccines, the scale of fiscal support and dependence on tourism influenced the speed of reopening and the extent of lasting losses. Transfers, credit guarantees and wage subsidies cushioned household incomes and business finances, but countries with limited fiscal resources had less capacity to sustain such support. (imf.org)
The International Labour Organization estimated that global working hours fell by 8.8% in 2020 relative to the fourth quarter of 2019—equivalent to 255 million full-time jobs. This measure combined reduced hours among employed people with employment losses; the separate decline in employment was 114 million people relative to 2019. Employment losses were greatest in the Americas and smaller in Europe, where job-retention programmes helped preserve employment relationships despite reduced hours. Women and younger workers experienced disproportionate losses: employment declined by 8.7% among young workers, compared with 3.7% among older workers. Informal workers were especially vulnerable because many worked in heavily affected sectors and lacked income protection; an ILO estimate identified approximately 1.6 billion informal workers as significantly affected by restrictions or employment in those sectors. (ilo.org)
Disruptions propagated through global value chains when factory closures interrupted supplies of intermediate components to producers elsewhere. Subsequent increases in goods demand encountered port congestion, labour shortages and limited shipping capacity, raising freight costs and delivery times. Semiconductor shortages particularly constrained vehicle production, illustrating how a missing component could halt assembly despite demand for finished products. These bottlenecks weakened the manufacturing recovery and contributed to inflation in 2021. The World Trade Organization reported that merchandise-trade volume fell by 5.3% in 2020, whereas commercial-services exports declined by 20% in nominal dollar terms. International tourism suffered a sharper contraction: the World Tourism Organization’s January 2021 assessment recorded a 74% fall in international arrivals during 2020, approximately one billion fewer arrivals than in 2019, affecting airlines, accommodation providers and tourism-dependent economies. (imf.org)
School closures interrupted instruction and widened inequalities in access to education. UNICEF reported in August 2020 that approximately 1.5 billion schoolchildren had been affected at the height of closures, and at least 463 million could not access remote learning. Television, radio and online provision did not eliminate disparities: poorer and rural households were less likely to possess suitable devices or connectivity, while access did not necessarily imply participation or effective learning. A 2022 joint assessment led by the World Bank estimated through simulations that “learning poverty”—inability to read and understand a simple text by age ten—in low- and middle-income countries had risen from 57% before the pandemic to approximately 70%. This was a modelled estimate rather than a direct worldwide assessment of children’s attainment. Prolonged closures, limited effectiveness of remote instruction and household-income shocks contributed to the projected deterioration. (unicef.org)
The mental health burden extended beyond people infected with SARS-CoV-2. In March 2022, the World Health Organization reported an estimated 25% increase in the global prevalence of anxiety and depression during the pandemic’s first year. Social isolation, bereavement, fear of infection, financial insecurity and increased caregiving responsibilities were identified as important stressors; younger people and women were particularly affected. These pressures coincided with interruptions to mental-health services and unequal access to remote care. (who.int)
The distribution of these consequences reflected existing social determinants of health. Informal and low-income workers faced acute income insecurity, while essential workers often continued working under conditions of exposure and sustained stress. In a United States survey conducted on 24–30 June 2020, 40.9% of 5,470 adult respondents reported at least one adverse mental- or behavioural-health condition. Reported burdens were disproportionately high among essential workers, unpaid adult caregivers, and Hispanic and Black respondents. The survey used symptom-screening instruments and self-reports rather than clinical diagnoses, and its cross-sectional findings did not establish that the pandemic alone caused the observed differences. (ilo.org)
Impact on health systems and medical research
Surges of COVID-19 admissions strained health systems through simultaneous shortages of intensive-care beds, medical equipment and specialist staff. Hospitals expanded capacity by postponing elective procedures, establishing temporary facilities, using private-sector resources and transferring critically ill patients between institutions or across borders. Physical beds alone were insufficient without personnel and equipment to support them. Medical oxygen became a particularly important constraint: on 25 February 2021, the World Health Organization (WHO) and partners estimated that more than half a million people with COVID-19 in low- and middle-income countries needed oxygen each day, requiring approximately 1.1 million cylinders daily. Supply depended on production facilities, transport, distribution equipment and trained personnel, rather than simply purchasing ventilators. (eurohealthobservatory.who.int)
The workforce experienced substantial losses alongside these material pressures. WHO estimated that 80,000–180,000 health and care workers died from COVID-19 between January 2020 and May 2021, with a central estimate of 115,500; these were modelled estimates rather than a complete count of registered occupational deaths. Disruption also extended beyond COVID-19 treatment. In WHO’s second global survey, published in April 2021 and based on responses from 135 countries and territories, approximately 90% reported at least one disruption to essential services. Staff redeployment, shortages of supplies, reduced attendance and financial barriers affected routine immunization, chronic-disease management and other care. Countries responded through measures including telemedicine, changes to prescribing arrangements and community-based service delivery. (who.int)
Clinical research demonstrated how large, coordinated randomized controlled trials could produce actionable evidence rapidly. The United Kingdom’s RECOVERY trial began in March 2020 and compared several treatments within a shared trial infrastructure. Its dexamethasone comparison assigned 2,104 hospitalized patients to the drug and 4,321 to usual care. Results announced on 16 June 2020 showed reduced mortality among patients receiving respiratory support, providing an early example of emergency research changing clinical practice within months. The organizational achievement was not merely accelerated recruitment: a common protocol and concurrent control group allowed treatment effects to be distinguished from changes in patient populations and care over time. (recoverytrial.net)
Research dissemination accelerated through preprints, which made manuscripts available before journal peer review. A bibliometric study led by Nicholas Fraser reported that, by the end of October 2020, more than 125,000 COVID-19 publications had appeared, including 30,260 preprints—approximately one quarter of the total. This accelerated access also exposed preliminary findings to journalists and policymakers before formal review. Sharing viral genomes supported another form of rapid collaboration: Victor Corman and colleagues developed an early RT-PCR diagnostic workflow using publicly available sequences, despite initially lacking virus isolates or original patient specimens. Their January 2020 study illustrated how sequence information could enable laboratories outside the outbreak area to begin developing diagnostic capacity. (journals.plos.org)
Technological advances drew on research established before the pandemic. Katalin Karikó and Drew Weissman’s work on modified messenger RNA, first published in 2005, showed how nucleoside modification could reduce unwanted inflammatory responses; subsequent studies demonstrated increased protein production. These findings helped enable the rapid development of mRNA vaccines and earned the researchers the 2023 Nobel Prize in Physiology or Medicine. Diagnostic innovation included the 2020 DETECTR assay developed by James Broughton and colleagues. It combined reverse transcription and isothermal amplification with CRISPR–Cas12 recognition and reporter cleavage, producing a result in approximately 30–40 minutes from extracted respiratory-swab RNA. This was an initially validated alternative diagnostic approach, not evidence that conventional laboratory testing had been universally replaced. (nobelprize.org)
Public communication had to distinguish established findings from provisional results while explaining changing evidence. WHO described an infodemic as an excessive volume of information, including false or misleading material, circulating during an outbreak. Such material could undermine trust in health authorities and interfere with protective behaviour. The wide circulation of preprints made their review status and uncertainty particularly relevant to reporting. Responses included monitoring public questions and rumours, communicating evidence in accessible formats and building partnerships beyond health institutions. In Lebanon, for example, WHO, UNICEF and the United Nations Development Programme worked with the Ministry of Information in July 2020 on a dedicated online resource for checking and countering circulating claims. (who.int)
Governance, equity and international cooperation
COVAX, launched in 2020 as the vaccine pillar of the Access to COVID-19 Tools Accelerator, combined international procurement, donor financing and support for vaccine delivery. Its co-leaders were Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations, UNICEF and the World Health Organization (WHO). The COVAX Advance Market Commitment financed free doses for eligible low- and lower-middle-income economies, linking pooled purchasing with support for transport, storage and administration. When COVAX closed on 31 December 2023, it had supplied nearly two billion doses to 146 economies; eligible lower-income economies subsequently obtained support through Gavi’s regular programmes. Nevertheless, its initial lack of cash reserves constrained early contracting, while export restrictions delayed large-volume deliveries until the third quarter of 2021. (who.int)
Access differed sharply by national income. On 20 May 2022, COVAX partners reported that 16% of people in low-income countries had received at least one vaccine dose, compared with 80% in high-income countries. By then, COVAX accounted for 82% of vaccine deliveries to low-income countries. Supply was not the only constraint: financing shortages, insufficient health workers, competing emergencies and difficulties reaching vulnerable populations also limited administration. WHO, UNICEF and Gavi established the COVID-19 Vaccine Delivery Partnership in January 2022 to provide country-specific assistance, including delivery planning and operational funding. These arrangements distinguished the international allocation of doses from the national health-system capacity needed to administer them. (who.int)
Intellectual-property negotiations addressed whether existing rules restricted the expansion of production. On 2 October 2020, India and South Africa proposed temporarily waiving specified obligations under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) for COVID-19 products. Supporters argued that the waiver would facilitate production and access; opponents disputed whether intellectual-property rights were a demonstrated barrier and emphasized existing TRIPS flexibilities. The narrower WTO decision adopted on 17 June 2022 allowed eligible developing-country members greater scope to authorize patented vaccine production without right-holder consent, including production for export, for five years. It did not constitute a general waiver covering all COVID-19 medical technologies. (wto.org)
Technology transfer pursued manufacturing capacity alongside these legal measures. WHO and the Medicines Patent Pool established an mRNA technology-transfer programme in 2021, centred on Afrigen Biologics in Cape Town. Afrigen’s role was to develop production technology, the South African Medical Research Council supported research, and Biovac became the first manufacturing partner. The hub model encompassed training, technical assistance, manufacturing procedures and quality control—not simply permission to use patents. Technology packages were intended for transfer to manufacturers in low- and middle-income countries, enabling regional production rather than exclusive dependence on imported finished doses. (who.int)
International information sharing operates through the legally binding International Health Regulations (IHR). National authorities must assess potentially significant events and notify WHO within 24 hours of an assessment identifying a qualifying event; subsequent communications include laboratory results, case and death counts, and response measures. National IHR Focal Points provide continuously available communication channels. Amendments adopted in 2024 entered into force on 19 September 2025 for most States Parties, introducing a “pandemic emergency” alert, National IHR Authorities to coordinate implementation, and provisions addressing equitable access to medical products and financing. Eleven of the 196 States Parties had rejected those amendments at their entry into force. WHO acts as the regulations’ secretariat but cannot compel national action. (who.int)
A separate WHO Pandemic Agreement was adopted on 20 May 2025 after more than three years of negotiations. Its proposed Pathogen Access and Benefit Sharing system links rapid sharing of pathogen materials and sequence information with equitable access to resulting vaccines, therapeutics and diagnostics; participating manufacturers would provide WHO rapid access targeting 20% of real-time production during a pandemic emergency. Negotiations on the implementing annex remained ongoing at the eighth intergovernmental working-group meeting, which concluded on 18 September 2026. Completion and adoption of that annex would allow the agreement to open for signature; entry into force requires 60 ratifications. The agreement expressly excludes WHO authority to impose national lockdowns, vaccination mandates or domestic legislation. (who.int)
Unresolved questions and future research
The origin of SARS-CoV-2 remains unresolved, but the competing hypotheses do not have equal evidential support. On 27 June 2025, the World Health Organization published an assessment by its Scientific Advisory Group for the Origins of Novel Pathogens (SAGO), chaired by virologist Marietjie Venter. The group concluded that the weight of available evidence favoured zoonotic transmission, either directly from bats or through an intermediate animal host. It nevertheless could not fully evaluate a laboratory-related origin because essential information was unavailable. Outstanding research needs include early patient genetic sequences, records of animals traded in Wuhan markets, and documentation of laboratory activities and biosafety conditions. These gaps make access to original samples and records, rather than further interpretation of the same public datasets alone, central to distinguishing possible routes of emergence. (who.int)
For long COVID, unresolved questions concern both the duration of disability and the identification of biologically distinct patient groups. RECOVER’s longitudinal studies include adults, pregnant participants, children and postmortem investigations, providing infrastructure for studying recovery trajectories and underlying mechanisms. A major obstacle is the absence of a definitive diagnostic biomarker: a 2024 RECOVER analysis found that routine laboratory measurements did not reliably distinguish participants with long COVID, and CDC guidance published in 2026 continued to state that no laboratory test could definitively diagnose or exclude it. Treatment research also requires distinguishing plausible mechanisms from demonstrated therapeutic benefit. In September 2026, NIH reported results from RECOVER-VITAL, involving 959 adults at 69 US sites: nirmatrelvir–ritonavir administered for up to 25 days did not improve cognitive, autonomic or exercise-intolerance outcomes compared with placebo. Blood-sample analyses were continuing to investigate viral persistence and treatment response. This result limits the demonstrated benefit of that regimen in the studied population; it does not establish that all patients share one mechanism of disease. (grants.nih.gov)
Broadly protective vaccines seek to redirect immunity towards viral structures shared across variants or related coronaviruses. One approach is a mosaic nanoparticle displaying different receptor-binding domains together. In work published in 2022, Pamela Bjorkman’s team at the California Institute of Technology developed mosaic-8, combining domains from eight SARS-like coronaviruses on particles carrying 60 domains. Their arrangement favours B cells recognizing conserved surfaces shared by neighbouring domains rather than features unique to one virus. Animal experiments demonstrated protection against diverse sarbecoviruses. A separate spike–ferritin nanoparticle platform produced cross-variant neutralizing responses in a phase 1 trial reported in 2024. These findings establish experimental routes towards broader protection, not proven protection against every coronavirus: breadth within the SARS-related sarbecovirus group is a narrower objective than a genuinely pan-coronavirus vaccine. (nih.gov)
Next-generation antiviral research must address resistance as well as potency. A 2024 study of persistent infections in 15 immunocompromised patients recovered infectious virus with mutations in both the main protease and RNA-dependent RNA polymerase after sequential nirmatrelvir–ritonavir and remdesivir treatment. The isolate showed reduced susceptibility to both drugs and retained transmission capacity in an animal model. Such observations provide a rationale for investigating combinations acting on different viral targets and for coupling treatment studies with genomic sequencing and laboratory susceptibility testing. They do not imply that resistance commonly accounts for treatment failure in ordinary short-duration infections. (nature.com)
Future surveillance extends beyond counting clinical cases. WHO’s environmental-surveillance guidance describes wastewater testing as a complementary means of detecting circulation, identifying rising or falling trends and monitoring variants. Linking these population signals with clinical outcomes and experimental characterization is important because sequence changes alone do not establish their effects on disease or countermeasure effectiveness. WHO also identifies animal populations and chronically infected individuals as important settings for monitoring viral evolution. In the United States, the Extensive Deer Genomic Surveillance project, initiated in 2023, combines testing and whole-genome sequencing in farmed and wild white-tailed deer to investigate animal infection and inform countermeasure development. These programmes address the possibility that viral persistence and evolution outside routinely sampled human populations could create sources of future outbreaks. (who.int)
References
- The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2nature.com
- Family: Coronaviridaeictv.global
- Molecular architecture of the SARS-CoV-2 virusccsb.scripps.edu
- A new coronavirus associated with human respiratory disease in Chinanature.com
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptornature.com
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitorpmc.ncbi.nlm.nih.gov
- Cell entry mechanisms of SARS-CoV-2pmc.ncbi.nlm.nih.gov
- Naming the coronavirus disease (COVID-19) and the virus that causes itwho.int
- Pneumonia of unknown cause – Chinawho.int
- Novel Coronavirus – Chinawho.int
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, Chinaidsociety.org
- The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemicpmc.ncbi.nlm.nih.gov
- A pneumonia outbreak associated with a new coronavirus of probable bat originnature.com
- Independent assessment of the origins of SARS-CoV-2 by SAGOcdn.who.int
- WHO Scientific advisory group issues report on origins of COVID-19who.int
- Scientific Brief: SARS-CoV-2 Transmissionarchive.cdc.gov
- Science Brief: SARS-CoV-2 and Surface (Fomite) Transmission for Indoor Community Environmentsarchive.cdc.gov
- COVID-19 | CDC Yellow Book™cdc.gov
- Clinical Presentation | Covid | CDCcdc.gov
- Temporal dynamics in viral shedding and transmissibility of COVID-19nature.com
- Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kongnature.com
- High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice — Skagit County, Washington, March 2020cdc.gov
- Management of Patients with Confirmed 2019-nCoVarchive.cdc.gov
- Underlying Conditions and the Higher Risk for Severe COVID-19cdc.gov
- People with Certain Medical Conditions and COVID-19 Risk Factorscdc.gov
- Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–October 3, 2020cdc.gov
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitorpubmed.ncbi.nlm.nih.gov
- Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cellsnature.com
- SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translationnature.com
- COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targetsnature.com
- Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19pubmed.ncbi.nlm.nih.gov
- SARS-CoV-2 infection and persistence in the human body and brain at autopsynature.com
- The RNA sensor MDA5 detects SARS-CoV-2 infectionnature.com
- Impaired type I interferon activity and inflammatory responses in severe COVID-19 patientspubmed.ncbi.nlm.nih.gov
- ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunitynature.com
- Autoantibodies against type I IFNs in patients with life-threatening COVID-19pubmed.ncbi.nlm.nih.gov
- Immunological memory to SARS-CoV-2 assessed for up to eight months after infectionpmc.ncbi.nlm.nih.gov
- A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021who.int
- Long COVID Clinical Guidancecdc.gov
- Post COVID-19 conditioncdn.who.int
- Clinical management of COVID-19: living guideline, June 2025iris.who.int
- Persistent complement dysregulation with signs of thromboinflammation in active Long Covidpubmed.ncbi.nlm.nih.gov
- The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: a systematic literature review and meta-analysis of the latest researchpmc.ncbi.nlm.nih.gov
- Clinical management of COVID-19iris.who.int
- Protocol V2who.int
- Overview of Testing for SARS-CoV-2cdc.gov
- Guidance for SARS-CoV-2 Rapid Testing in Point-of-Care Settingscdc.gov
- Antigen-detection in the diagnosis of SARS-CoV-2 infectionwho.int
- SARS-CoV-2 Viral Shedding and Rapid Antigen Test Performance — Respiratory Virus Transmission Network, November 2022–May 2023cdc.gov
- At-Home COVID-19 Diagnostic Tests: Frequently Asked Questionsfda.gov
- Interim Guidelines for COVID-19 Antibody Testingarchive.cdc.gov
- Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network — 12 States, April–August 2020cdc.gov
- Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022cdc.gov
- Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages — United States, May 2023–September 2024cdc.gov
- Clinical Laboratory COVID-19 Response Call, June 15, 2020cdc.gov
- Spike mutation D614G alters SARS-CoV-2 fitnessnature.com
- SARS-CoV-2 spike D614G change enhances replication and transmissionnature.com
- WHO announces simple, easy-to-say labels for SARS-CoV-2 Variants of Interest and Concernemro.who.int
- Highlights on COVID-19 vaccines from recent SAGEcdn.who.int
- The N501Y spike substitution enhances SARS-CoV-2 infection and transmissionnature.com
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralizationnature.com
- SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasionnature.com
- Update on Omicronwho.int
- Enhancing response to Omicron SARS-CoV-2 variantwho.int
- TAG-VE statement on Omicron sublineages BQ.1 and XBBwho.int
- Initial Risk Evaluation of JN.1, 19 December 2023who.int
- The different types of COVID-19 vaccineswho.int
- Coronavirus disease (COVID-19): Pandemic overview—Where are we now?who.int
- COVID-19 vaccineswho.int
- Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices—United States, 2024–2025cdc.gov
- Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years—VISION and IVY Networks, September 2024–January 2025cdc.gov
- Statement on the antigen composition of COVID-19 vaccineswho.int
- Health workers at risk, older adults and residents of long-term care facilities to be prioritized for COVID-19 vaccinationwho.int
- COVAX calls for urgent action to close vaccine equity gapwho.int
- COVID-19 Treatment Clinical Care for Outpatientscdc.gov
- IDSA Guidelines on the Treatment and Management of Patients with COVID-19idsociety.org
- Bebtelovimab No Longer Authorized to Treat COVID-19medi-calrx.dhcs.ca.gov
- FDA Revokes EUAs for Four Monoclonal Antibody Productscontent.govdelivery.com
- COVID-19 Clinical Care Pathwaywho.int
- Clinical management of COVID-19: Living guideline, 18 August 2023who.int
- Coronavirus disease (COVID-19): Contact tracingwho.int
- Transmission of SARS-CoV-2: implications for infection prevention precautionswho.int
- Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020stacks.cdc.gov
- Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealandnature.com
- Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealandnature.com
- Special Focus: The importance of fit, filtration and breathability of non-medical (fabric) masks in the context of COVID-19who.int
- Coronavirus disease (COVID-19): Ventilation and air conditioningwho.int
- Impact of community masking on COVID-19: A cluster-randomized trial in Bangladeshpubmed.ncbi.nlm.nih.gov
- Impact of community masking on COVID-19: A cluster-randomized trial in Bangladeshpmc.ncbi.nlm.nih.gov
- Inferring the effectiveness of government interventions against COVID-19pmc.ncbi.nlm.nih.gov
- From COVID-19 learning disruption to recovery: A snapshot of UNESCO’s work in education in 2020unesco.org
- WHO COVID-19 Global Risk Assessment- Version 10who.int
- COVID-19 circulation | WHO COVID-19 dashboarddata.who.int
- Interim statement on hybrid immunity and increasing population seroprevalence rateswho.int
- 9 million excess deaths associated with the COVID-19 pandemic in 2020 and 2021who.int
- Global excess deaths associated with COVID-19, January 2020 - December 2021who.int
- Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implicationspmc.ncbi.nlm.nih.gov
- Impact of Hospital Strain on Excess Deaths During the COVID-19 Pandemic — United States, July 2020–July 2021cdc.gov
- Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022cdc.gov
- Weekly epidemiological update on COVID-19 - 25 January 2022who.int
- Estimated COVID-19 Periodicity and Correlation with SARS-CoV-2 Spike Protein S1 Antigenic Diversity, United Stateswwwnc.cdc.gov
- Listings of WHO's response to COVID-19who.int
- Coronavirus disease 2019 (COVID-19): Situation Report – 51who.int
- ACT-Accelerator one year onwho.int
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global accesswho.int
- COVID-19 Response: Living with COVID-19gov.uk
- COVID-19 Surveillance After Expiration of the Public Health Emergency Declaration ― United States, May 11, 2023cdc.gov
- Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemicwho.int
- WHO Director-General's opening remarks at the media briefing – 5 May 2023who.int
- We need a just transition and a green recovery from COVID-19ilo.org
- World trade primed for strong but uneven recovery after COVID-19 pandemic shockwto.org
- COVID-19: At least a third of the world’s schoolchildren unable to access remote learning during school closures, new report saysunicef.org
- 70% of 10-Year-Olds now in Learning Poverty, Unable to Read and Understand a Simple Textworldbank.org
- The State of Global Learning Poverty: 2022 Updatethedocs.worldbank.org
- COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwidewho.int
- Intensive care capacities during COVID-19eurohealthobservatory.who.int
- COVID-19 oxygen emergency impacting more than half a million people in low- and middle-income countries every day, as demand surgeswho.int
- Health and Care Worker Deaths during COVID-19who.int
- COVID-19 continues to disrupt essential health services in 90% of countrieswho.int
- Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19recoverytrial.net
- The evolving role of preprints in the dissemination of COVID-19 research and their impact on the science communication landscapejournals.plos.org
- Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCRpubmed.ncbi.nlm.nih.gov
- Press release: The Nobel Prize in Physiology or Medicine 2023nobelprize.org
- CRISPR–Cas12-based detection of SARS-CoV-2nature.com
- The COVID-19 infodemicwho.int
- How to fight the COVID-19 infodemicemro.who.int
- COVID-19 vaccinations shift to regular immunization as COVAX draws to a closewho.int
- Members discuss intellectual property response to the COVID-19 pandemicwto.org
- TRIPS Council welcomes MC12 TRIPS waiver decision, discusses possible extensionwto.org
- mRNA technology transfer hubwho.int
- WHO/MPP mRNA Technology Transfer Programmewho.int
- WHO guidance for use of Annex 2who.int
- Emergencies: Ten things you need to do to implement the International Health Regulationswho.int
- Amended International Health Regulations enter into forcewho.int
- World Health Assembly adopts historic Pandemic Agreement to make the world more equitable and safer from future pandemicswho.int
- Member States advance negotiations on pathogen access and benefit-sharing ahead of UN General Assembly meeting on pandemicswho.int
- The NIH RECOVER Program Announces Plan to Request Ancillary Studiesgrants.nih.gov
- SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trialpmc.ncbi.nlm.nih.gov
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infectionsnature.com
- Environmental surveillance for SARS-CoV-2 to complement other public health surveillancewho.int
- Tracking SARS-CoV-2 variantswho.int
- EXTENSIVE SARS-COV-2 GENOMIC SURVEY SUPPORTING FARMED WHITE TAILED DEER HEALTHnal.usda.gov